ERBB2 and breast cancer: The oncogenic activity of p21 in breast cancer has been reported by its inability to inhibit CDKs irrespective of its presence in high levels and by its association with the up-regulation of HER2/Neu which results in the poor prognosis of breast cancer [56,57].